v3.22.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Current assets    
Cash and cash equivalents $ 92,241 $ 114,141
Short-term investments 8,000  
Research and development tax credits receivable 412 356
Prepaid expenses 4,068 4,299
Other receivables 245 127
Total current assets 104,966 118,923
Operating lease assets 641 711
Property and equipment 192 215
Total assets 105,799 119,849
Current liabilities    
Accounts payable and accrued liabilities 4,412 6,551
Operating lease liabilities 198 224
Total current liabilities 4,610 6,775
Operating lease liabilities (net of current portion) 433 474
Total liabilities 5,043 7,249
Shareholders' Equity    
Common shares, no par value, unlimited shares authorized 29,917,326 shares issued and outstanding as of March 31, 2022, 29,897,559 shares issued and outstanding as of December 31, 2021 251,990 251,901
Pre-funded warrants - 12,327,780 issued and outstanding as of March 31, 2022 and 12,327,780 as of December 31, 2021 52,941 52,941
Additional paid-in capital 17,785 15,711
Cumulative translation adjustment (1,634) (1,634)
Accumulated deficit (220,326) (206,319)
Total shareholders' equity 100,756 112,600
Total liabilities and shareholders' equity $ 105,799 $ 119,849